Erschienen in:
10.10.2017 | Research Letter
Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma
verfasst von:
Mélanie Claps, Sara Cerri, Salvatore Grisanti, Barbara Lazzari, Vittorio Ferrari, Elisa Roca, Paola Perotti, Massimo Terzolo, Sandra Sigala, Alfredo Berruti
Erschienen in:
Endocrine
|
Ausgabe 1/2018
Einloggen, um Zugang zu erhalten
Excerpt
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumor that is actively secreting in approximately 50% of adult patients. Cushing’s syndrome is the most commonly associated endocrine disorder [
1] that negatively influences the outcome of ACC patients, due to cortisol-related comorbidities [
2] and the immunosuppressive effects of cortisol excess that may promote tumor progression [
3]. The management of ACC patients is challenging and demanding because physicians have to deal with either oncological or endocrinological issues [
4]. …